CorMedix (CRMD) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$462.2M

Revenue (quarter)

$101.9M

Revenue growth (year over year)

+156.52%

Gross profit (trailing twelve months)

$382.6M

Gross margin

82.78%

Net income (trailing twelve months)

$187.2M

Net income (quarter)

$26.0M

Net income growth (year over year)

+31.07%

Net margin

40.49%

Return on equity

54.93%

EPS (trailing twelve months)

$2.46

Book value per share

$5.93

P/E (trailing twelve months)

3.08

Price to book

1.25

Debt to assets

49.03%

Payout ratio

—

Dividend yield

—

Company profile

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

• Is CorMedix (CRMD) profitable?

  Yes. CorMedix earned $187.2M in net income over the trailing twelve months, a net margin of 40.49%.

• How much revenue does CorMedix (CRMD) make?

  CorMedix generated $462.2M in revenue over the trailing twelve months, up 156.52% year over year.

• What is CRMD's P/E ratio?

  CorMedix trades at 3.1 times trailing twelve-month earnings, on an EPS of $2.46.

• How do I buy stock in CorMedix (CRMD)?

  CRMD trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.